The hGM-CSF/hIL-3 NOG is an immunodeficient CIEA NOG mouse
altered to express human GM-CSF and IL-3 cytokines. The resulting transgenic mouse model supports the differentiation of human myeloid cell lineages and potentiates increased efficiency of hematopoietic stem cell and
human immune system engraftment compared to the core NOG mouse.
The model was designed to express relatively low cytokine levels, which maintains the long-term stability of engraftment by preventing the exhaustion of the stem cell pool. This stability makes it a flexible platform for the generation of humanized mice
- Supports myeloid lineage engraftment through human IL-3 and GM-CSF cytokine expression
- More efficient human hematopoietic stem cell (HSC) engraftment
- Higher levels of myeloid cell differentiation following human HSC engraftment
- Low cytokine expression and long-term HSC engraftment
Research applications include the generation of humanized mouse models
oncology, infectious disease, and regenerative medicine.
Orders by weight:
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH
Origin: The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The hGM-CSF/hIL-3 SCID mouse was developed in the laboratory of Dr. Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The linearized hIL-3 and hGM-CSF transgenes were co-injected into zygotes from BDF1 females x C57BL/6J scid. The transgenic SCID mouse was backcrossed more than 12 generations on to the CIEA NOG mouse® background. Taconic received stock in 2014, and the line was derived through embryo transfer.
Availability: Available now*
*Please note that advance order is encouraged for order of male mice. There is a minimal 4-week advance notice required on orders of male older than 3 weeks of age.
- Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γ mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
- Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.
- Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.